COST ANALYSIS OF SCREENING ACCORDING TO ECCO GUIDELINES FOR PREVENTION OF OPPORTUNISTIC INFECTIONS IN INFLIXIMAB-TREATED IBD PATIENTS

被引：1
|
作者：
Metz, A. [1 ]
Elliott, T. [2 ]
Hull, B. [2 ]
Duncan, J. [2 ]
Sastrillo, M. [2 ]
Smith, M. [2 ]
Sanderson, J. D. [2 ]
Irving, P. M. [2 ]
机构：
[1] Addenbrookes Hosp, Cambridge, England
[2] Guys & St Thomas Hosp, London SE1 9RT, England
来源：
GUT | 2011年 / 60卷
关键词：
D O I：
10.1136/gut.2011.239301.301
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A142 / A142
页数：1
相关论文
共 50 条
  • [1] Cost Analysis of Screening According to ECCO Guidelines for Prevention of Opportunistic Infections in Infliximab-Treated IBD Patients
    Metz, Andrew J.
    Elliott, Tim
    Hull, Bradley
    Duncan, Julie
    Sastrillo, Marlene
    Smith, Melissa A.
    Sanderson, Jeremy D.
    Irving, Peter M.
    GASTROENTEROLOGY, 2011, 140 (05) : S772 - S772
  • [2] Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention
    C. Garcia-Vidal
    S. Rodríguez-Fernández
    S. Teijón
    M. Esteve
    M. Rodríguez-Carballeira
    J. M. Lacasa
    G. Salvador
    J. Garau
    European Journal of Clinical Microbiology & Infectious Diseases, 2009, 28 : 331 - 337
  • [3] Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention
    Garcia-Vidal, C.
    Rodriguez-Fernandez, S.
    Teijon, S.
    Esteve, M.
    Rodriguez-Carballeira, M.
    Lacasa, J. M.
    Salvador, G.
    Garau, J.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2009, 28 (04) : 331 - 337
  • [4] Audit of Prevention of Opportunistic Infections in Immunosuppressed Patients With IBD: How Close are We to ECCO Guidelines?
    Elliott, Tim
    Duncan, Julie
    Patel, Pritash
    Smith, Melissa
    Sanderson, Jeremy D.
    Irving, Peter M.
    GASTROENTEROLOGY, 2010, 138 (05) : S535 - S535
  • [5] Frequency of B-cell subsets in infliximab-treated paediatric IBD patients
    Schnell, A.
    Schwarz, B.
    Wahlbuhl-Becker, M.
    Allabauer, I.
    Rechenauer, T.
    Siebenlist, G.
    Kaspar, S.
    Ehrsam, C.
    Rueckel, A.
    Rascher, W.
    Hoerning, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S228 - S228
  • [6] Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD
    Ray K.
    Nature Reviews Gastroenterology & Hepatology, 2021, 18 (5) : 286 - 286
  • [7] Factors Associated With Large Increases in Self-Reported Health Status in Infliximab-Treated IBD Patients
    Jones, Jennifer
    Perampaladas, Kuhan
    Williamson, Martin
    Kanters, Steve
    Thorlund, Kristian
    GASTROENTEROLOGY, 2014, 146 (05) : S445 - S445
  • [8] Prevention of opportunistic infections in patients with inflammatory bowel disease and implications of the ECCO consensus in Belgium
    Rahier, J. F.
    Moreels, T.
    De Munter, P.
    D'Haens, G.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2010, 73 (01) : 41 - 45
  • [9] A MODEL UTILIZING WEEK 6 INFLIXIMAB TROUGH LEVELS PREDICTS ONE YEAR PERSISTENT REMISSION IN INFLIXIMAB-TREATED PEDIATRIC IBD PATIENTS
    Singh, Namita
    Arora, Yogesh
    Yakub, Jasmine
    Cook-Wiens, Galen
    Hester, Kelly
    Kondragunta, Venkateswarlu
    Jain, Anjali
    Rabizadeh, Shervin
    Dubinsky, Marla
    GASTROENTEROLOGY, 2018, 154 (06) : S825 - S825
  • [10] Opportunistic infections in patients treated with infliximab for Crohn's disease and rheumatoid arthritis
    Gershon, SK
    Slifman, NR
    Braun, MM
    GASTROENTEROLOGY, 2002, 122 (04) : A470 - A470
12345